353 related articles for article (PubMed ID: 12882847)
1. Renoprotective effects of adding angiotensin II receptor blocker to maximal recommended doses of ACE inhibitor in diabetic nephropathy: a randomized double-blind crossover trial.
Rossing K; Jacobsen P; Pietraszek L; Parving HH
Diabetes Care; 2003 Aug; 26(8):2268-74. PubMed ID: 12882847
[TBL] [Abstract][Full Text] [Related]
2. Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy.
Jacobsen P; Andersen S; Rossing K; Jensen BR; Parving HH
Kidney Int; 2003 May; 63(5):1874-80. PubMed ID: 12675866
[TBL] [Abstract][Full Text] [Related]
3. Optimal dose of candesartan for renoprotection in type 2 diabetic patients with nephropathy: a double-blind randomized cross-over study.
Rossing K; Christensen PK; Hansen BV; Carstensen B; Parving HH
Diabetes Care; 2003 Jan; 26(1):150-5. PubMed ID: 12502672
[TBL] [Abstract][Full Text] [Related]
4. Dual blockade of the renin-angiotensin system in diabetic nephropathy: a randomized double-blind crossover study.
Rossing K; Christensen PK; Jensen BR; Parving HH
Diabetes Care; 2002 Jan; 25(1):95-100. PubMed ID: 11772908
[TBL] [Abstract][Full Text] [Related]
5. Additive effect of ACE inhibition and angiotensin II receptor blockade in type I diabetic patients with diabetic nephropathy.
Jacobsen P; Andersen S; Jensen BR; Parving HH
J Am Soc Nephrol; 2003 Apr; 14(4):992-9. PubMed ID: 12660333
[TBL] [Abstract][Full Text] [Related]
6. Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study.
Rossing K; Schjoedt KJ; Smidt UM; Boomsma F; Parving HH
Diabetes Care; 2005 Sep; 28(9):2106-12. PubMed ID: 16123474
[TBL] [Abstract][Full Text] [Related]
7. Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy.
Andersen S; Tarnow L; Rossing P; Hansen BV; Parving HH
Kidney Int; 2000 Feb; 57(2):601-6. PubMed ID: 10652037
[TBL] [Abstract][Full Text] [Related]
8. Effect of low-dose dual blockade of renin-angiotensin system on urinary TGF-beta in type 2 diabetic patients with advanced kidney disease.
Song JH; Cha SH; Lee HJ; Lee SW; Park GH; Lee SW; Kim MJ
Nephrol Dial Transplant; 2006 Mar; 21(3):683-9. PubMed ID: 16330466
[TBL] [Abstract][Full Text] [Related]
9. Dual blockade of the renin-angiotensin system in type 1 patients with diabetic nephropathy.
Jacobsen P; Andersen S; Rossing K; Hansen BV; Parving HH
Nephrol Dial Transplant; 2002 Jun; 17(6):1019-24. PubMed ID: 12032191
[TBL] [Abstract][Full Text] [Related]
10. Effects of dual blockade of renin-angiotensin system in type 2 diabetes mellitus patients with diabetic nephropathy.
Krairittichai U; Chaisuvannarat V
J Med Assoc Thai; 2009 May; 92(5):611-7. PubMed ID: 19459520
[TBL] [Abstract][Full Text] [Related]
11. Add-on angiotensin receptor blockade with maximized ACE inhibition.
Agarwal R
Kidney Int; 2001 Jun; 59(6):2282-9. PubMed ID: 11380832
[TBL] [Abstract][Full Text] [Related]
12. [Clinical study of the month. The CALM study assessing the combination of an angiotensin-converting enzyme inhibitor and an angiotensin II receptor antagonist in the treatment of diabetic nephropathy].
Philips JC; Weekers L; Scheen AJ
Rev Med Liege; 2001 Feb; 56(2):126-8. PubMed ID: 11294048
[TBL] [Abstract][Full Text] [Related]
13. Targeting albumin excretion rate in the treatment of the hypertensive diabetic patient with renal disease.
Krimholtz MJ; Karalliedde J; Thomas S; Bilous R; Viberti G
J Am Soc Nephrol; 2005 Mar; 16 Suppl 1():S42-7. PubMed ID: 15938033
[TBL] [Abstract][Full Text] [Related]
14. Combination of half doses of angiotensin type 1 receptor antagonist and angiotensin-converting enzyme inhibitor in diabetic nephropathy.
Fujisawa T; Ikegami H; Ono M; Nishino M; Noso S; Kawabata Y; Ogihara T
Am J Hypertens; 2005 Jan; 18(1):13-7. PubMed ID: 15691611
[TBL] [Abstract][Full Text] [Related]
15. The effects of dual blockade of the renin-angiotensin system on urinary protein and transforming growth factor-beta excretion in 2 groups of patients with IgA and diabetic nephropathy.
Song JH; Lee SW; Suh JH; Kim ES; Hong SB; Kim KA; Kim MJ
Clin Nephrol; 2003 Nov; 60(5):318-26. PubMed ID: 14640237
[TBL] [Abstract][Full Text] [Related]
16. Long-term comparison of losartan and enalapril on kidney function in hypertensive type 2 diabetics with early nephropathy.
Lacourcière Y; Bélanger A; Godin C; Hallé JP; Ross S; Wright N; Marion J
Kidney Int; 2000 Aug; 58(2):762-9. PubMed ID: 10916100
[TBL] [Abstract][Full Text] [Related]
17. Optimal dose of lisinopril for renoprotection in type 1 diabetic patients with diabetic nephropathy: a randomised crossover trial.
Schjoedt KJ; Astrup AS; Persson F; Frandsen E; Boomsma F; Rossing K; Tarnow L; Rossing P; Parving HH
Diabetologia; 2009 Jan; 52(1):46-9. PubMed ID: 18974967
[TBL] [Abstract][Full Text] [Related]
18. Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy.
Schjoedt KJ; Rossing K; Juhl TR; Boomsma F; Tarnow L; Rossing P; Parving HH
Kidney Int; 2006 Aug; 70(3):536-42. PubMed ID: 16775595
[TBL] [Abstract][Full Text] [Related]
19. Differences between nisoldipine and lisinopril on glomerular filtration rates and albuminuria in hypertensive IDDM patients with diabetic nephropathy during the first year of treatment.
Rossing P; Tarnow L; Boelskifte S; Jensen BR; Nielsen FS; Parving HH
Diabetes; 1997 Mar; 46(3):481-7. PubMed ID: 9032106
[TBL] [Abstract][Full Text] [Related]
20. Effect of dual blockade of the renin-angiotensin system on the progression of type 2 diabetic nephropathy: a randomized trial.
Fernandez Juarez G; Luño J; Barrio V; de Vinuesa SG; Praga M; Goicoechea M; Cachofeiro V; Nieto J; Fernández Vega F; Tato A; Gutierrez E;
Am J Kidney Dis; 2013 Feb; 61(2):211-8. PubMed ID: 22939518
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]